Cystic Fibrosis Treatment

Aug 05, 2025

Anbogen’s ABT-301 Cleared by FDA for Phase I/II Colorectal Cancer Trial; Dyne’s DYNE-251 Gets FDA Breakthrough Tag for Duchenne Muscular Dystrophy; BMS’s BREYANZI Accepted for FDA Priority Review in MZL; Clarametyx’s CMTX-101 Earns FDA Fast Track and QIDP for Infections; Anixa Begins FDA-Approved IND Transfer for Phase II Breast Cancer Vaccine Trial

Jan 12, 2024

Is Bacteriophage a Potential Game-Changer in the Realm of Cystic Fibrosis Treatment?

Feb 08, 2021

Cystic Fibrosis Market: A Rapidly Expanding Playing Field for Mid-Cap Pharma

Newsletter/Whitepaper